INTERVENTION 1:	Intervention	0
Phase I: Everolimus (Dose Level 1) and Trastuzumab	Intervention	1
everolimus	CHEBI:68478	9-19
Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.	Intervention	2
duration	PATO:0001309	6-14
everolimus	CHEBI:68478	126-136
mouth	UBERON:0000165	145-150
disease	DOID:4,OGMS:0000031	202-209
INTERVENTION 2:	Intervention	3
Phase I: Everolimus (Dose Level 2) and Trastuzumab	Intervention	4
everolimus	CHEBI:68478	9-19
Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.	Intervention	5
duration	PATO:0001309	6-14
everolimus	CHEBI:68478	126-136
mouth	UBERON:0000165	146-151
disease	DOID:4,OGMS:0000031	203-210
Inclusion Criteria:	Eligibility	0
Histologically or cytologically confirmed invasive breast cancer, with stage IV disease	Eligibility	1
breast cancer	DOID:1612	51-64
disease	DOID:4,OGMS:0000031	80-87
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as greater than or equal to 20mm with conventional techniques or as greater than or equal to 10mm with spiral CT scan.	Eligibility	2
disease	DOID:4,OGMS:0000031	11-18
ct	BAO:0002125	219-221
Primary tumor or metastasis must overexpress HER2	Eligibility	3
Patient must have received 1-2 prior chemotherapeutic regiments for metastatic breast cancer and must have been off treatment for at least three weeks.	Eligibility	4
patient	HADO:0000008,OAE:0001817	0-7
breast cancer	DOID:1612	79-92
Patient must have received and progressed on at least 1 prior trastuzumab-containing regimen, but not more than 2, in the metastatic setting.	Eligibility	5
patient	HADO:0000008,OAE:0001817	0-7
Patients may have received prior radiation therapy	Eligibility	6
Patients may have received hormonal therapy in the adjuvant or metastatic setting	Eligibility	7
adjuvant	CHEBI:60809	51-59
18 years of age or older	Eligibility	8
age	PATO:0000011	12-15
Life expectancy of greater than 6 months	Eligibility	9
Normal organ and marrow function as defined in the protocol	Eligibility	10
organ	UBERON:0000062	7-12
function	BAO:0003117,BFO:0000034	24-32
Left ventricular ejection fraction (LVEF) greater than or equal to the institutional lower limit of normal	Eligibility	11
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
Exclusion Criteria:	Eligibility	12
Treatment with any investigational drug within 4 weeks	Eligibility	13
drug	CHEBI:23888	35-39
Long-term treatment, over 3 months, with a systemic steroid or another immunosuppressive agent	Eligibility	14
steroid	CHEBI:35341	52-59
immunosuppressive agent	CHEBI:35705	71-94
Other malignancies within the past 3 years, except for adequately treated carcinoma of teh cervix or basal-or squamous-cell carcinoma of the skin	Eligibility	15
carcinoma	HP:0030731,DOID:305	74-83
carcinoma	HP:0030731,DOID:305	124-133
Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001	Eligibility	16
function	BAO:0003117,BFO:0000034	31-39
disease	DOID:4,OGMS:0000031	60-67
An active, bleeding diathesis or an oral anti-vitamin K medication	Eligibility	17
active	PATO:0002354	3-9
Prior treatment with an mTOR inhibitor	Eligibility	18
mtor inhibitor	CHEBI:68481	24-38
History of non-compliance with medical regimens	Eligibility	19
history	BFO:0000182	0-7
Unwillingness or inability to comply with the protocol	Eligibility	20
Major surgery within 2 weeks before study entry	Eligibility	21
surgery	OAE:0000067	6-13
Patients with active brain metastases or leptomeningeal carcinomatosis	Eligibility	22
active	PATO:0002354	14-20
brain	UBERON:0000955	21-26
Patients who have experienced grade 1 or grade 2 hypersensitivity reactions to prior trastuzumab therapy are eligible ONLY IF these reactions did not prevent further administration	Eligibility	23
hypersensitivity	GO:0002524,DOID:1205	49-65
Severe and/or uncontrolled intercurrent medical condition, psychiatric illness or a social situation that could limit their ability to comply with the study requirements.	Eligibility	24
severe	HP:0012828	0-6
condition	PDRO:0000129	48-57
Pregnant or breast-feeding women	Eligibility	25
HIV positive patients	Eligibility	26
Known hypersensitivity to RAD001 (everolimus) or other rapamycins	Eligibility	27
hypersensitivity	GO:0002524,DOID:1205	6-22
everolimus	CHEBI:68478	34-44
Outcome Measurement:	Results	0
Maximum Tolerated Dose (MTD)	Results	1
mtd	BAO:0001248	24-27
The MTD is determined by the number of patients who experience a dose limiting toxicity (DLT). The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached. Dose Limiting Toxicities (DLTs) were defined as follows (CTCAE v4.0):	Results	2
mtd	BAO:0001248	4-7
mtd	BAO:0001248	99-102
mtd	BAO:0001248	223-226
Any grade 4 hematologic toxicity, excluding anemia.	Results	3
anemia	HP:0001903,DOID:2355	44-50
Any grade 3 or 4 nonhematologic toxicity, except for nausea, vomiting, diarrhea, or hyperlipidemia that responds promptly (within 24 hours for nausea, vomiting, and diarrhea and within 1 week for hyperlipidemia) to appropriate treatment, and except for cardiac toxicity which will be assessed after 12 weeks of treatment.	Results	4
nausea	HP:0002018	53-59
nausea	HP:0002018	143-149
vomiting	HP:0002013	61-69
vomiting	HP:0002013	151-159
diarrhea	HP:0002014,DOID:13250	71-79
diarrhea	HP:0002014,DOID:13250	165-173
hyperlipidemia	HP:0003077	84-98
hyperlipidemia	HP:0003077	196-210
week	UO:0000034	187-191
week	UO:0000034	302-306
Need to hold >1 dose of trastuzumab or > 7 doses of RAD001 within the first 3 weeks because of the presence of toxicity.	Results	5
Time frame: Cycle One (first 21 days of treatment)	Results	6
time	PATO:0000165	0-4
Results 1:	Results	7
Arm/Group Title: Phase I: Everolimus (Dose Level 1) and Trastuzumab	Results	8
everolimus	CHEBI:68478	26-36
Arm/Group Description: Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.	Results	9
duration	PATO:0001309	29-37
everolimus	CHEBI:68478	149-159
mouth	UBERON:0000165	168-173
disease	DOID:4,OGMS:0000031	225-232
Overall Number of Participants Analyzed: 3	Results	10
Measure Type: Number	Results	11
Unit of Measure: participants with DLT  0	Results	12
Results 2:	Results	13
Arm/Group Title: Phase I: Everolimus (Dose Level 2) and Trastuzumab	Results	14
everolimus	CHEBI:68478	26-36
Arm/Group Description: Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.	Results	15
duration	PATO:0001309	29-37
everolimus	CHEBI:68478	149-159
mouth	UBERON:0000165	169-174
disease	DOID:4,OGMS:0000031	226-233
Overall Number of Participants Analyzed: 3	Results	16
Measure Type: Number	Results	17
Unit of Measure: participants with DLT  0	Results	18
Adverse Events 1:	Adverse Events	0
Total: 0/3 (0.00%)	Adverse Events	1
Muco/stomatitis (symptom) oral cavity 0/3 (0.00%)	Adverse Events	2
symptom	OGMS:0000020	17-24
oral cavity	UBERON:0000167	26-37
Fatigue 0/3 (0.00%)	Adverse Events	3
fatigue	HP:0012378	0-7
Vascular access-Thrombosis/embolism  [1]0/3 (0.00%)	Adverse Events	4
Leukocytes 0/3 (0.00%)	Adverse Events	5
Lymphopenia 0/3 (0.00%)	Adverse Events	6
lymphopenia	HP:0001888,DOID:614	0-11
Neutrophils 0/3 (0.00%)	Adverse Events	7
Platelets 0/3 (0.00%)	Adverse Events	8
Hypokalemia 0/3 (0.00%)	Adverse Events	9
hypokalemia	HP:0002900,DOID:4500	0-11
Thrombosis/thrombus/embolism  [2]0/3 (0.00%)	Adverse Events	10
Adverse Events 2:	Adverse Events	11
Total: 1/3 (33.33%)	Adverse Events	12
Muco/stomatitis (symptom) oral cavity 0/3 (0.00%)	Adverse Events	13
symptom	OGMS:0000020	17-24
oral cavity	UBERON:0000167	26-37
Fatigue 0/3 (0.00%)	Adverse Events	14
fatigue	HP:0012378	0-7
Vascular access-Thrombosis/embolism  [1]0/3 (0.00%)	Adverse Events	15
Leukocytes 0/3 (0.00%)	Adverse Events	16
Lymphopenia 1/3 (33.33%)	Adverse Events	17
lymphopenia	HP:0001888,DOID:614	0-11
Neutrophils 0/3 (0.00%)	Adverse Events	18
Platelets 0/3 (0.00%)	Adverse Events	19
Hypokalemia 0/3 (0.00%)	Adverse Events	20
hypokalemia	HP:0002900,DOID:4500	0-11
Thrombosis/thrombus/embolism  [2]0/3 (0.00%)	Adverse Events	21
